EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: a whole-exome sequence analysis

Waleed Mohammed Bawazir, Muhammad Ihtesham Khan, Mohannad Saeed Hazzazi iD, Ammar Abdullah Basabrain, Muhammad Tariq Masood Khan iD, Sami Siraj, Majed Naser Almashjary, Osman Radhwi iD, Steve Harakeh, Yasar Mehmood Yousafzai

PeerJ · 2025

DOI: 10.7717/peerj.20038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Waleed Mohammed Bawazir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Research Unit, King Fahd Medical Research Center, King Abdul Aziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: beta-Thalassemia, Thalidomide, Genes, Modifier. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research (DSR), King Abdulaziz University (KAU), Deanship of Scientific Research (DSR) at King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thalidomide induces fetal hemoglobin and renders most thalassemia patients transfusion-independent. Some patients, however, do not respond. Underlying genetic variations responsible for variable responses to thalidomide are unexplored. Aims and objectives To discover genetic variations that influence response to thalidomide in transfusion-dependent beta-thalassemia patients.

Methods

Twenty beta-thalassemia patients (14 excellent responders and six non-responders) who had received thalidomide were included in the study by a non-probability purposive sampling technique. Patients who showed a rise of >2 mg/dl in hemoglobin level and/or whose hemoglobin levels reached 9 gm/dl without blood transfusions were designated as excellent responders. Patients whose hemoglobin levels did not show an increment rise of >2 and/or whose hemoglobin levels did not rise above 5.9 gm/dl and needed blood transfusions to maintain optimal hemoglobin levels were designated as non-responders. DNA was extracted, and whole-exome sequencing was performed on an Illumina HiSeq System. Aligning and variant calling were done by the Sentieon software. Annotation was done by Annovar.

Results

The age of study participants ranged from 1–12 years, with a mean of 5.45 ± 3.81 years. There were 17 (85%) males and three (15%) females. A total of 222,180 germline variants were identified across 20 subjects, from which 24 candidate variants across 24 genes were identified. The three most common polymorphisms in the excellent responder group were found in the exon region of CHI3L1 (rs880633), NPNT (rs35132891), and ZNF 208 (rs10425763), which were found in 92%, 85%, and 71% cases, respectively. The commonest polymorphisms in the non-responder group were found in the PM20D1 gene (rs7518979), LGR6 (rs75658797), MYH15 (rs4299484), and RESF1 (rs3207618), each of which was found in 66.6% cases.

Conclusion

This study shows a significant association of single-nucleotide polymorphisms rs880633, rs35132891, and rs10425763 with excellent response status, while rs7518979, rs75658797, rs4299484, and rs3207618 are associated with non-response status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaThalidomideGenes, ModifierHumansFemaleMaleBlood TransfusionChildChild, PreschoolInfantExome Sequencing

Stichwörter der Autor:innen

CHI3L1LGR6NPNTThalidomideTransfusion dependent thalassemiars10425763rs3207618rs35132891rs7518979rs880633

Substanzen

Thalidomide

Autor:innen und Institutionen

  • Hematology Research Unit, King Fahd Medical Research Center, King Abdul Aziz University, Jeddah, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, King Abdul Aziz University, Jeddah, Saudi Arabia.
  • Department of Pathology, Khyber Medical College, Peshawar, Khyber Pakhtunkhwa, Pakistan.
  • Institute of Pathology and Diagnostic Medicine, Khyber Medical University, Peshawar, Pakistan.
  • King Fahd Medical Research Center, Animal House Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Medicine, Pak International Medical College, Peshawar, Pakistan.

ORCID-Profile: Mohannad Saeed Hazzazi, Muhammad Tariq Masood Khan, Osman Radhwi

Förderung

  • Deanship of Scientific Research (DSR)
  • King Abdulaziz University (KAU)
  • Deanship of Scientific Research (DSR) at King Abdulaziz University

Zitieren

APA

Bawazir, W. M., Khan, M. I., Hazzazi, M. S., Basabrain, A. A., Khan, M. T. M., Siraj, S., Almashjary, M. N., Radhwi, O., Harakeh, S., & Yousafzai, Y. M. (2025). Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: a whole-exome sequence analysis. PeerJ. https://doi.org/10.7717/peerj.20038

Vancouver

Bawazir WM, Khan MI, Hazzazi MS, Basabrain AA, Khan MTM, Siraj S, et al. Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: a whole-exome sequence analysis. PeerJ. 2025. doi:10.7717/peerj.20038

BibTeX
@article{Bawazir2025,
  author = {Bawazir, Waleed Mohammed and Khan, Muhammad Ihtesham and Hazzazi, Mohannad Saeed and Basabrain, Ammar Abdullah and Khan, Muhammad Tariq Masood and Siraj, Sami and Almashjary, Majed Naser and Radhwi, Osman and Harakeh, Steve and Yousafzai, Yasar Mehmood},
  title = {Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: a whole-exome sequence analysis},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.20038}
}
Kostenlos starten →